The lead plaintiffs representing the class are described starting on p. 9.
The complaint is long (163 pp.) but you might take a look at the section that starts on page 34, paragraph 103.
For anyone who wants to be an investor in any development-stage biotech, there is some interesting information there about how the FDA works and communicates with companies.